Department of Precision Genomics, Intermountain Healthcare, Salt Lake City, UT, USA.
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
J Genet Couns. 2020 Aug;29(4):625-633. doi: 10.1002/jgc4.1278. Epub 2020 Apr 18.
Transgender (TG) individuals have higher rates of mortality associated with cancer diagnoses, in part due to avoidance of gender-assigned cancer screenings resulting in later stages at diagnosis. Knowledge about the risks of breast or gynecological cancer in TG and nonbinary (NB) persons receiving gender-affirming hormone therapy is limited. Even less information exists regarding the subset of individuals with genetic predisposition for these malignancies. We performed a retrospective literature review of studies from the last 15 years on breast cancer rates and identified risks in TG persons. An accumulating body of data on breast cancer incidence in TG persons suggests higher than previously believed rates of breast cancer in TG women compared with cisgender men and risk correlating with duration of hormone use. Few studies have examined other cancer risks in TG populations. To date, only three publications address the association with BRCA1/2 mutation presence and breast cancer incidence in TG persons. Meanwhile, there is growing awareness and social acceptance of TG/NB identities coupled with recognition of gender dysphoria at increasingly earlier ages. No information directly addressing cancer risk counseling in TG/NB adolescents and young adults with a family history of cancer or hereditary cancer syndrome exists. Whether the presence of a known genetic predisposition or strong family cancer history may affect cancer risk in these populations is unknown, leading to significant gaps in clinicians' ability to accurately and appropriately estimate cancer risks and counsel those with genetic predisposition on the risks/benefits associated with surgical options and the initiation, duration, and dosing of gender-affirming hormone therapies. A series of three cases illustrates the utility of cancer risk assessment and genetic testing in TG/NB adolescents and young adults, and the unique challenges and unanswered questions that are encountered in the process.
跨性别(TG)个体的癌症相关死亡率较高,部分原因是他们避免接受性别指定的癌症筛查,导致诊断时已处于晚期。关于接受性别肯定激素治疗的 TG 和非二元(NB)个体的乳腺癌或妇科癌症风险知之甚少。对于这些恶性肿瘤遗传易感性的亚组个体,相关信息就更少了。我们对过去 15 年中关于乳腺癌发病率的研究进行了回顾性文献综述,并确定了 TG 个体的风险因素。越来越多的数据表明,与顺性别男性相比,TG 女性的乳腺癌发病率高于先前认为的水平,且与激素使用时间相关。很少有研究检查 TG 人群中的其他癌症风险。迄今为止,只有三篇文献探讨了 BRCA1/2 突变存在与 TG 个体乳腺癌发病率之间的关联。同时,人们越来越意识到 TG/NB 身份,并认识到性别焦虑症在越来越早的年龄出现。目前尚无关于具有癌症家族史或遗传性癌症综合征的 TG/NB 青少年和年轻人的癌症风险咨询的直接信息。是否存在已知的遗传易感性或强烈的家族癌症史会影响这些人群的癌症风险尚不清楚,这导致临床医生准确适当地评估癌症风险并为具有遗传易感性的个体提供与手术选择、性别肯定激素治疗的开始、持续时间和剂量相关的风险/获益的能力存在显著差距。三个病例系列说明了在 TG/NB 青少年和年轻人中进行癌症风险评估和基因检测的效用,以及在该过程中遇到的独特挑战和未解决的问题。